EP3624837
And-FGFR2 mótefni í samsetningu með lyfjameðferðarmiðlum í krabbameinsmeðhöndlun
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
15.5.2018EP published:
30.7.2025EP application number:
18730518.0
EP translation filed:
22.9.2025Grant published:
15.10.2025EPO information:
European Patent Register
Max expiry date:
14.5.2038Expiry date:
14.5.2026
Title in English:
ANTI-FGFR2 ANTIBODIES IN COMBINATION WITH CHEMOTHERAPY AGENTS IN CANCER TREATMENTLanguage of the patent:
English
Timeline
Today
15.5.2018EP application
30.7.2025EP Publication
22.9.2025Translation submitted
15.10.2025Registration published
14.5.2026Expires
Owner
Name:
Five Prime Therapeutics, Inc.Address:
111 Oyster Point Boulevard, South San Francisco, CA 94080, US
Inventor
Name:
COLLINS, Helen L.Address:
South San Francisco California 94080, US
Name:
HNATYSZYN, JamesAddress:
South San Francisco California 94080, US
Name:
XIANG, HongAddress:
South San Francisco California 94080, US
Name:
ZHANG, XiangAddress:
South San Francisco California 94080, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201762507053 PDate:
16.5.2017Country:
US
Number:
201762581992 PDate:
6.11.2017Country:
US
Classification
Categories:
A61K 39/00, A61K 39/395, C07K 16/22, C07K 16/28, A61P 35/00